上海清算所港股晨报-20260116

Market Overview - The Hang Seng Index (HSI) faces short-term resistance at 27,188 points, with expectations of two interest rate cuts in 2026 following the Federal Reserve's December decision to lower rates by 0.25 basis points [1] - The market anticipates policy initiatives in the first quarter of 2026 aimed at boosting domestic demand and achieving technological self-reliance, with potential for further monetary easing [1][2] - Recent adjustments in financing margin ratios by the Shanghai and Shenzhen stock exchanges may lead to short-term market corrections, impacting the inflow of foreign capital into Hong Kong stocks [1] Corporate News - Dongpeng Beverage plans a secondary listing in Hong Kong, aiming to raise over 7.8 billion HKD, with subscriptions expected to begin this month [3] - Alibaba has integrated its AI assistant "Qianwen" with Taobao and Alipay, enabling functionalities such as food delivery and flight bookings [3] - CK Hutchison is reportedly seeking a valuation of 30 billion USD for a potential IPO of Watsons Group [3][9] - WuXi Biologics intends to reduce its stake by 3.8%, raising approximately 5.8 billion HKD, and will no longer be a major shareholder [3][9] Macro Focus - The People's Bank of China (PBOC) has lowered the interest rate on structural monetary policy tools by 0.25 percentage points, aiming to enhance credit support for key sectors [7] - In December, new loans in China reached 910 billion CNY, exceeding expectations, while total social financing increased by 2.21 trillion CNY [7] - The National Development and Reform Commission has announced that fixed asset investment by the State Grid will reach 4 trillion CNY during the 14th Five-Year Plan, marking a 40% increase from the previous plan [7] Sector Insights - The biopharmaceutical sector in China has seen a record high in new drug licensing deals, indicating sustained demand in the industry [6] - Defensive sectors are expected to attract capital as market risk appetite decreases [6]